ISSN: 2278-0238

薬学および生命科学における研究開発の国際ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Chloroquine and Hydroxychloroquine in Coronavirus Disease-19: The Real Savior or a False-Positive Testament

Dr. Smithi Karia H

A novel coronavirus disease (COVID-19) has spread all around the world. The progression from initial signs to a diagnosis of acute respiratory failure is usually related to spontaneous cytokine production. There is a growing need to classify appropriate medicines for treatment care. The inhibitory effect of chloroquine (CQ) is potential. However, CQ can lead to serious side effects. Various studies recommend hydroxychloroquine (HCO) have similar antiviral effect as of CQ and maybe a better therapeutic solution. Therefore, we aim to explore the mechanism by which HCQ can inhibit replication of coronavirus. Materials and Methods: A retrospective study was carried out using online databases from 2003 to 2020, Results: The obtained results showed that HCQ can inhibit viral replication and entry inside the cell through raising lysosomal pH and hinding to specific receptors on cells, thereby, preventing viral entry. Conclusion: HCQ has a better safety profile than CQ and also modulates cytokine syndrome. However, further studies are needed to explore this mechanism.